OR-RADISYS
11.10.2021 08:02:04 CEST | Business Wire | Press release
Radisys® Corporation , a global leader of open telecom solutions, today announced its Connect Open Broadband solution showcase in Booth A24 at Broadband World Forum 2021, with the event exhibition taking place October 13-14 in Amsterdam, and the online event occurring October 11-15. Radisys will present live demonstrations that enable broadband service providers to transform their networks, simplify network operations, and be prepared to meet their customers’ changing needs. Radisys will demonstrate triple-play services, including high-speed internet and video streaming over Gigabit-PON (G-PON) and XGS-PON, and its Smart Home portfolio —including the Radisys Reach Smart Home Gateway and customizable mobile application—along with a sampling of available sensors, cameras and other devices that work together as an integrated solution.
Radisys will join other industry thought leaders in sessions exploring broadband innovation:
- Rajesh Chundury, VP of Customers Solutions, will present, “Advance Your FTTx Network with Cloud-Native Containerized Solutions for PON” on October 11 at 10:30am in the virtual session and live in-person October 14 from 2:10pm-2:30pm.
- Chundury will also participate in the Open Networking Foundation’s workshop “Taking opensource to production in broadband network with VOLTHA, a community view” on October 13, 3:00pm-5:00pm. The discussion will also feature experts from Adtran, Deutsche Telekom, Netsia and Türk Telekom.
The Radisys showcase will feature key solutions from its broadband and Smart Home portfolios. The demonstrations will include the Connect Broadband Access Controller (CBAC)-C (Centralized) and CBAC-D (Distributed) deployments using Radisys’ RLT-1600G and RLT-1600X Optical Line Terminals (OLTs) for fiber to the x (FTTX) deployments.
- Radisys’ CBAC software enables service providers to evolve their fiber networks with an open software solution that facilitates faster product innovation cycles, increased automation, and deeper network visibility.
- The Radisys Combo PON OLT features full PON port flexibility and enables broadband providers to leverage G-PON technology while also providing the option to expand their network and rollout XGS-PON deployments using the same OLT hardware at their pace and optimizing their cost model.
- Radisys’ Optical Network Terminals (ONTs) are built with inherent efficiencies and scalability to support data, voice, video and other broadband services for residential and commercial subscribers on fiber networks.
- Radisys’ Smart Home solutions help service providers broaden the utility of their data plans with life-enriching services and features that consumers want, to create new revenue streams and increase average revenue per user.
“Radisys is delivering best-in-class devices and leading software solutions that add value to the broadband ecosystem, elevating broadband service provider offerings and enhancing their data plans,” said Harris Razak, senior vice president of Broadband Access, Radisys. “Broadband World Forum 2021 is an exciting opportunity to showcase our portfolio that enables service providers to expand their fiber networks with world class solutions and leverage an open device ecosystem to create new revenue streams.”
To see the technology demonstrations, or to meet with Radisys’ open telecom experts at Broadband World Forum 2021, contact open@radisys.com .
About Radisys
Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit www.Radisys.com .
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211010005025/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom